Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1413)	8/7/2000 6:33:31 PM
From: IRWIN JAMES FRANKEL	Respond to of 52153

Great post Harold, "5. Avonex is only the best of a poor lot of treatments for MS. Like psoraiasis, MS has lots of companies searching for a better treatment (including Biogen)." I do see this one a bit differently. In exacerbating/remitting MS Avonex is as good as Copaxonne but not better theraputically. But when you consider side effects Copaxonne seems to be winning. In the more aggressive forms of MS BetaSeron seems to be better. From a purely business sense Avonex is the slowest growing of the three. ij